Emerging drugs in colorectal cancer.
A raft of novel agents with different modes of action is finally challenging the position of 5-fluorouracil (5-FU) as the gold standard treatment for colorectal cancer. Oral fluoropyrimidines, topoisomerase I inhibitors and new generation platinum compounds are all currently being investigated. There is also increasing interest in the development and use of biological therapies, which may allow treatments to become tailored to individual patients and cause less toxicity than conventional cytotoxics. It is hoped that with the development of these new drugs, the response rates and survival for patients with colorectal cancer will improve from the poor prognosis that many face at present.
Scott
Lucy
L
Department of Medical Oncology, Beatson Oncology Center, Western Infirmary, Dumbarton Road, Glasgow, Scotland, UK.
Fraser
Judith
J
Cassidy
Jim
J
D000818:Animals; D000970:Antineoplastic Agents / Q000145:classification / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends*
D000970:Antineoplastic Agents